dl-2-(difluoromethyl) ornithine
Small moleculeexperimental
Clinical trial activity
9 trials · 14 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Jun 12, 2018 (NCT03536728)
Timeline
Indications
Studied for
- Astrocytoma · Phase 1
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Diabetes Mellitus, Type 1 · Phase 2
- Diffuse Intrinsic Pontine Glioma · Phase 1/Phase 2
- Endometrial Neoplasms · Phase 1/Phase 2
- Esophageal Neoplasms · Phase 1/Phase 2
- Glioblastoma · Phase 1
- Glioma · Phase 1/Phase 2
- Head and Neck Neoplasms · Phase 1/Phase 2
- Lung Neoplasms · Phase 1/Phase 2
- Medulloblastoma · Phase 2
- Melanoma · Phase 1/Phase 2
- Mesothelioma · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Osteosarcoma · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 1/Phase 2
- Prostatic Neoplasms · Phase 2
- Sarcoma, Ewing · Phase 1/Phase 2
- Stomach Neoplasms · Phase 1/Phase 2
- Thyroid Cancer, Papillary · Phase 1/Phase 2
- Uterine Cervical Neoplasms · Phase 1/Phase 2
Mechanism of action
- Ornithine decarboxylaseINHIBITOR
ODC1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07287917 | Phase 1/Phase 2 (Phase 2) | Dec 18, 2025 | Aminex Therapeutics, Inc. |
| NCT06892678 | Phase 1/Phase 2 (Phase 2) | Apr 7, 2025 | Johns Hopkins University, Yeshiva University |
| NCT06219174 | Phase 1/Phase 2 (Phase 2) | Aug 7, 2024 | University of South Florida |
| NCT06059118 | Phase 2 | Oct 4, 2023 | Department of Defense, Johns Hopkins University, Panbela Therapeutics, Prostate Cancer Foundation |
| NCT05879367 | Phase 1 | Jul 24, 2023 | Orbus Therapeutics, Inc., University of Utah |
| NCT05594563 | Phase 2 | Dec 31, 2022 | Cancer Prevention Pharmaceuticals, Inc., Indiana University, Juvenile Diabetes Research Foundation |
| NCT05500508 | Phase 1/Phase 2 (Phase 2) | Aug 8, 2022 | Aminex Therapeutics, Inc. |
| NCT04696029 | Phase 2 | Mar 29, 2021 | Atrium Medical Corporation, University of Florida |
| NCT03536728 | Phase 1 | Jun 12, 2018 | Aminex Therapeutics, Inc. |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (14)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aminex Therapeutics, Inc. | For profit | 3 | 3 | 2 | 2018 |
| Johns Hopkins University | Academic/Hospital | 2 | 1 | 1 | 2023 |
| Atrium Medical Corporation | For profit | 1 | 0 | 1 | 2021 |
| Cancer Prevention Pharmaceuticals, Inc. | For profit | 1 | 0 | 1 | 2022 |
| Department of Defense | Government | 1 | 0 | 1 | 2023 |
| Indiana University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Juvenile Diabetes Research Foundation | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Orbus Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2023 |
| Panbela Therapeutics | For profit | 1 | 0 | 1 | 2023 |
| Prostate Cancer Foundation | Academic/Hospital | 1 | 0 | 1 | 2023 |
| University of Florida | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of South Florida | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Utah | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Yeshiva University | Academic/Hospital | 1 | 1 | 1 | 2025 |
14 organizations
Page 1 / 1